BiotechTube
Mammoth Biosciences

Mammoth Biosciences

Brisbane, United States· Est.
mammoth.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $413M

Overview

Mammoth Biosciences, founded in 2017 and co-founded by CRISPR pioneer Jennifer Doudna, is a private biotech developing a next-generation CRISPR platform. The company's core innovation lies in discovering and engineering novel, ultracompact Cas enzymes (like its NanoCas systems) designed to overcome the delivery bottlenecks of in vivo gene editing, particularly for extrahepatic tissues. With a pipeline advancing towards the clinic, strategic partnerships, and a dual focus on therapeutics and diagnostics, Mammoth aims to unlock the full potential of genetic medicine.

RNA & Gene Therapy

Technology Platform

Proprietary platform for discovering and engineering novel, ultracompact CRISPR-Cas systems (e.g., Casφ, Cas14) to enable efficient AAV delivery for in vivo gene editing.

Funding History

4
Total raised:$413M
Series C$195M
Series B$150M
Series A$45M
Seed$23M

Opportunities

The primary opportunity is to unlock in vivo gene editing for a wide range of genetic diseases affecting extrahepatic tissues (e.g., muscle, CNS) by solving the AAV delivery challenge with ultracompact Cas enzymes.
A validated platform could lead to a broad pipeline of proprietary and partnered therapies, capturing value in a large, underserved market.

Risk Factors

Key risks include the unproven safety and efficacy of novel Cas enzymes in humans, intense competition from other gene-editing companies, and the inherent challenges of AAV delivery, including immunogenicity and manufacturing scalability.
Clinical failure of a lead program would significantly impact the platform's valuation.

Competitive Landscape

Mammoth competes with established CRISPR leaders (CRISPR Therapeutics, Intellia, Editas, Beam) who are also advancing in vivo editing. Its key differentiation is its library of proprietary, ultracompact Cas proteins designed for easier delivery. It also faces potential competition from newer gene editing modalities (e.g., ARCUS nucleases, TALENs) and delivery technologies.

More companies in CRISPR / Gene Editing →More companies in United States →